These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome. Haws R; Brady S; Davis E; Fletty K; Yuan G; Gordon G; Stewart M; Yanovski J Diabetes Obes Metab; 2020 Nov; 22(11):2133-2140. PubMed ID: 32627316 [TBL] [Abstract][Full Text] [Related]
24. Setmelanotide: what does it mean for clinical care of patients with obesity? Ryan DH Lancet Diabetes Endocrinol; 2020 Dec; 8(12):933-935. PubMed ID: 33137294 [No Abstract] [Full Text] [Related]
25. Setmelanotide: A Novel Targeted Treatment for Monogenic Obesity. Pressley H; Cornelio CK; Adams EN J Pharm Technol; 2022 Dec; 38(6):368-373. PubMed ID: 36311304 [No Abstract] [Full Text] [Related]
26. Setmelanotide, a Novel, Selective Melanocortin Receptor-4 Agonist Exerts Anti-inflammatory Actions in Astrocytes and Promotes an Anti-inflammatory Macrophage Phenotype. Kamermans A; Verhoeven T; van Het Hof B; Koning JJ; Borghuis L; Witte M; van Horssen J; de Vries HE; Rijnsburger M Front Immunol; 2019; 10():2312. PubMed ID: 31636637 [TBL] [Abstract][Full Text] [Related]
27. Chronic delivery of α-melanocyte-stimulating hormone in rat hypothalamus using albumin-alginate microparticles: effects on food intake and body weight. Lucas N; Legrand R; Breton J; Déchelotte P; Edwards-Lévy F; Fetissov SO Neuroscience; 2015 Apr; 290():445-53. PubMed ID: 25637491 [TBL] [Abstract][Full Text] [Related]
28. Setmelanotide optimization through fragment-growing, molecular docking in-silico method targeting MC4 receptor. Jia X; Fan S; Dong W; Li S; Zhang Y; Ma Y; Wang S J Biomol Struct Dyn; 2023; 41(24):15411-15420. PubMed ID: 37126536 [TBL] [Abstract][Full Text] [Related]
29. Spiroindane based amides as potent and selective MC4R agonists for the treatment of obesity. He S; Ye Z; Dobbelaar PH; Sebhat IK; Guo L; Liu J; Jian T; Lai Y; Franklin CL; Bakshi RK; Dellureficio JP; Hong Q; Weinberg DH; Macneil T; Tang R; Strack AM; Tamvakopoulos C; Peng Q; Miller RR; Stearns RA; Chen HY; Chen AS; Fong TM; Wyvratt MJ; Nargund RP Bioorg Med Chem Lett; 2010 Aug; 20(15):4399-405. PubMed ID: 20598882 [TBL] [Abstract][Full Text] [Related]
30. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Kingsberg SA; Clayton AH; Portman D; Williams LA; Krop J; Jordan R; Lucas J; Simon JA Obstet Gynecol; 2019 Nov; 134(5):899-908. PubMed ID: 31599840 [TBL] [Abstract][Full Text] [Related]
32. Control of appetite, blood glucose, and blood pressure during melanocortin-4 receptor activation in normoglycemic and diabetic NPY-deficient mice. da Silva AA; Freeman JN; Hall JE; do Carmo JM Am J Physiol Regul Integr Comp Physiol; 2018 Apr; 314(4):R533-R539. PubMed ID: 29351428 [TBL] [Abstract][Full Text] [Related]
33. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Simon JA; Kingsberg SA; Portman D; Williams LA; Krop J; Jordan R; Lucas J; Clayton AH Obstet Gynecol; 2019 Nov; 134(5):909-917. PubMed ID: 31599847 [TBL] [Abstract][Full Text] [Related]
34. New Drugs for Rare Disorders. Aschenbrenner DS Am J Nurs; 2021 Feb; 121(2):27. PubMed ID: 33497125 [TBL] [Abstract][Full Text] [Related]
36. Melanocortin 4 receptor-mediated hyperphagia and activation of neuropeptide Y expression in the dorsomedial hypothalamus during lactation. Chen P; Williams SM; Grove KL; Smith MS J Neurosci; 2004 Jun; 24(22):5091-100. PubMed ID: 15175378 [TBL] [Abstract][Full Text] [Related]
37. A novel non-synonymous mutation in the melanocortin-4 receptor gene (MC4R) in a 2-year-old Austrian girl with extreme obesity. Rettenbacher E; Tarnow P; Brumm H; Prayer D; Wermter AK; Hebebrand J; Biebermann H; Hinney A; Widhalm K Exp Clin Endocrinol Diabetes; 2007 Jan; 115(1):7-12. PubMed ID: 17286227 [TBL] [Abstract][Full Text] [Related]
38. Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder. Mayer D; Lynch SE Ann Pharmacother; 2020 Jul; 54(7):684-690. PubMed ID: 31893927 [No Abstract] [Full Text] [Related]
39. Melanocortin-4 receptor agonists for the treatment of obesity. Emmerson PJ; Fisher MJ; Yan LZ; Mayer JP Curr Top Med Chem; 2007; 7(11):1121-30. PubMed ID: 17584132 [TBL] [Abstract][Full Text] [Related]
40. Current Mechanistic and Pharmacodynamic Understanding of Melanocortin-4 Receptor Activation. Sharma S; Garfield AS; Shah B; Kleyn P; Ichetovkin I; Moeller IH; Mowrey WR; Van der Ploeg LHT Molecules; 2019 May; 24(10):. PubMed ID: 31100979 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]